查看文章

Multimodal molecular imaging has revolutionized both clinical practice and biomedical research. PET/CT performed using the positron emission tomography (PET) radiotracer 18F-fluorodeoxyglucose (18F-FDG) has become a pivotal modality for imaging a variety of pathologies and is particularly useful in the detection and evaluation of cancers. Hybrid whole-body PET/CT yields complementary sets of structural data and metabolic or functional information in one harmonious setting and allows for successful utilization in clinical settings with results superior to both PET and CT individually.

However, despite its many benefits as an imaging modality, 18F-FDG PET/CT has several limitations, most notably being the ionizing radiation and lower soft tissue resolution associated with CT. In this setting, where high spatial resolution, soft-tissue contrast, or radiation exposure are